Mephenytoin (BioDeep_00000013241)
Secondary id: BioDeep_00001869156
human metabolite blood metabolite
代谢物信息卡片
5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione
化学式: C12H14N2O2 (218.1055)
中文名称: 美芬妥英, 美芬妥因
谱图信息:
最多检出来源 Danio rerio(blood) 16.67%
分子结构信息
SMILES: CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2
InChI: InChI=1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)
描述信息
Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. It is generally reserved for treatment of individuals refractory to less toxic agents. Mephenytoin and oxazolidinedione derivatives are associated with higher incidences of blood dyscrasias compared to other anticonvulsants. As such, these agents should not be used concurrently.
N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics > N03AB - Hydantoin derivatives
C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent
D002491 - Central Nervous System Agents > D000927 - Anticonvulsants
同义名列表
19 个代谢物同义名
5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione; 5-Ethyl-3-methyl-5-phenylhydantoin; 5 Ethyl 3 methyl 5 phenylhydantoin; Phenylethylmethylhydantoin; Phenetoin, methyl; Methyl hydantoin; Methyl phenetoin; Methylphenetoin; (S)-Mephenytoin; DL-Mephenytoin; Mephenytoinum; Mephenytoine; MEPHENYTOIN; Mefenitoina; Phenantoin; Mephentoin; Mefenetoin; Mesantoin; Methoin
数据库引用编号
16 个数据库交叉引用编号
- ChEBI: CHEBI:179062
- ChEBI: CHEBI:6757
- KEGG: C20130
- PubChem: 107921
- PubChem: 4060
- HMDB: HMDB0014673
- DrugBank: DB00532
- ChEMBL: CHEMBL1743264
- ChEMBL: CHEMBL861
- Wikipedia: Mephenytoin
- MeSH: Mephenytoin
- chemspider: 3920
- CAS: 70989-04-7
- CAS: 50-12-4
- PMhub: MS000027656
- PubChem: 135626590
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Pierre Baumann, Gilles Bertschy, Fritz Ramseier, Rico Nil. Plasma Concentrations and Cardiovascular Effects of Citalopram Enantiomers After Oral Versus Infusion Citalopram Therapy in Dextromethorphan-Mephenytoin-Phenotyped Patients With Major Depression.
Therapeutic drug monitoring.
2021 06; 43(3):436-442. doi:
10.1097/ftd.0000000000000824. [PMID: 33060488] - Pierre Baumann, Chin B Eap, Markus Gastpar. The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients.
Basic & clinical pharmacology & toxicology.
2020 May; 126(5):444-447. doi:
10.1111/bcpt.13373. [PMID: 31814297] - Li-Ya Liu, Yong-Long Han, Jin-Hui Zhu, Qi Yu, Quan-Jun Yang, Jin Lu, Cheng Guo. A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates.
Biomedical chromatography : BMC.
2015 Mar; 29(3):437-44. doi:
10.1002/bmc.3294. [PMID: 25098274] - Pius S Fasinu, Patrick J Bouic, Bernd Rosenkranz. The inhibitory activity of the extracts of popular medicinal herbs on CYP1A2, 2C9, 2C19 and 3A4 and the implications for herb-drug interaction.
African journal of traditional, complementary, and alternative medicines : AJTCAM.
2014; 11(4):54-61. doi:
10.4314/ajtcam.v11i4.9. [PMID: 25392581] - Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Dec; 40(12):2332-41. doi:
10.1124/dmd.112.047068. [PMID: 22961681] - G Zadoyan, D Rokitta, S Klement, A Dienel, R Hoerr, T Gramatté, U Fuhr. Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers.
European journal of clinical pharmacology.
2012 May; 68(5):553-60. doi:
10.1007/s00228-011-1174-5. [PMID: 22189672] - Maki Hasegawa, Harunobu Tahara, Ryo Inoue, Masakazu Kakuni, Chise Tateno, Junko Ushiki. Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Mar; 40(3):474-80. doi:
10.1124/dmd.111.042754. [PMID: 22126990] - Junichi Azuma, Tomoko Hasunuma, Masanori Kubo, Masaya Miyatake, Toshiko Koue, Koushi Higashi, Tsutomu Fujiwara, Sachiko Kitahara, Tamiki Katano, Sumiko Hara. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
European journal of clinical pharmacology.
2012 Jan; 68(1):29-37. doi:
10.1007/s00228-011-1094-4. [PMID: 21739267] - Nicolas A Stewart, Shama C Buch, Thomas P Conrads, Robert A Branch. A UPLC-MS/MS assay of the "Pittsburgh cocktail": six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilution.
The Analyst.
2011 Feb; 136(3):605-12. doi:
10.1039/c0an00643b. [PMID: 21107456] - C Kragelund, C Hansen, J Reibel, B Nauntofte, K Brosen, S B Jensen, L A Torpet. Can the genotype or phenotype of two polymorphic drug metabolising cytochrome P450-enzymes identify oral lichenoid drug eruptions?.
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
2010 Jul; 39(6):497-505. doi:
10.1111/j.1600-0714.2010.00897.x. [PMID: 20492431] - Yasuhiro Uno, Kiyomi Matsuno, Chika Nakamura, Masahiro Utoh, Hiroshi Yamazaki. Identification and characterization of CYP2C18 in the cynomolgus macaque (Macaca fascicularis).
The Journal of veterinary medical science.
2010 Feb; 72(2):225-8. doi:
10.1292/jvms.09-0341. [PMID: 19940391] - Hao Chen, Michael Zientek, Mehran Jalaie, Yanhua Zhang, Christopher Bigge, Abdul Mutlib. Characterization of cytochrome P450-mediated bioactivation of a compound containing the chemical scaffold, 4,5-dihydropyrazole-1-carboxylic acid-(4-chlorophenyl amide), to a chemically reactive p-chlorophenyl isocyanate intermediate in human liver microsomes.
Chemical research in toxicology.
2009 Sep; 22(9):1603-12. doi:
10.1021/tx900167y. [PMID: 19697924] - M I Veiga, S Asimus, P E Ferreira, J P Martins, I Cavaco, V Ribeiro, T N Hai, M G Petzold, A Björkman, M Ashton, J P Gil. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
European journal of clinical pharmacology.
2009 Apr; 65(4):355-63. doi:
10.1007/s00228-008-0573-8. [PMID: 18979093] - Angelo A Izzo, Edzard Ernst. Interactions between herbal medicines and prescribed drugs: an updated systematic review.
Drugs.
2009; 69(13):1777-98. doi:
10.2165/11317010-000000000-00000. [PMID: 19719333] - Fengping Li, Mahendra D Chordia, Tao Huang, Timothy L Macdonald. In vitro nimesulide studies toward understanding idiosyncratic hepatotoxicity: diiminoquinone formation and conjugation.
Chemical research in toxicology.
2009 Jan; 22(1):72-80. doi:
10.1021/tx800152r. [PMID: 19053182] - Susanne Löfgren, Stina Ekman, Ylva Terelius, Ronny Fransson-Steen. Few alterations in clinical pathology and histopathology observed in a CYP2C18&19 humanized mice model.
Acta veterinaria Scandinavica.
2008 Nov; 50(?):47. doi:
10.1186/1751-0147-50-47. [PMID: 19038035] - Shaoyu Zhang, Naining Song, Quansheng Li, Huirong Fan, Changxiao Liu. Liquid chromatography/tandem mass spectrometry method for simultaneous evaluation of activities of five cytochrome P450s using a five-drug cocktail and application to cytochrome P450 phenotyping studies in rats.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2008 Aug; 871(1):78-89. doi:
10.1016/j.jchromb.2008.06.034. [PMID: 18614408] - Susanne Löfgren, R Michael Baldwin, Masahiro Hiratsuka, Annelie Lindqvist, Anne Carlberg, Sarah C Sim, Meint Schülke, Michael Snait, Anne Edenro, Ronny Fransson-Steen, Ylva Terelius, Magnus Ingelman-Sundberg. Generation of mice transgenic for human CYP2C18 and CYP2C19: characterization of the sexually dimorphic gene and enzyme expression.
Drug metabolism and disposition: the biological fate of chemicals.
2008 May; 36(5):955-62. doi:
10.1124/dmd.107.019349. [PMID: 18276835] - Tobias Klaassen, Alexander Jetter, Dorota Tomalik-Scharte, Dirk Kasel, Julia Kirchheiner, Ulrich Jaehde, Uwe Fuhr. Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity.
European journal of clinical pharmacology.
2008 Apr; 64(4):387-98. doi:
10.1007/s00228-007-0416-z. [PMID: 18071681] - Sara Asimus, Doaa Elsherbiny, Trinh N Hai, Britt Jansson, Nguyen V Huong, Max G Petzold, Ulrika S H Simonsson, Michael Ashton. Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects.
Fundamental & clinical pharmacology.
2007 Jun; 21(3):307-16. doi:
10.1111/j.1472-8206.2007.00471.x. [PMID: 17521300] - U Fuhr, A Jetter, J Kirchheiner. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach.
Clinical pharmacology and therapeutics.
2007 Feb; 81(2):270-83. doi:
10.1038/sj.clpt.6100050. [PMID: 17259951] - Ulrich Klotz. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.
Clinical pharmacokinetics.
2007; 46(4):271-9. doi:
10.2165/00003088-200746040-00001. [PMID: 17375979] - Reginald F Frye, Nathalie K Zgheib, Gary R Matzke, Diego Chaves-Gnecco, Mordechai Rabinovitz, Obaid S Shaikh, Robert A Branch. Liver disease selectively modulates cytochrome P450--mediated metabolism.
Clinical pharmacology and therapeutics.
2006 Sep; 80(3):235-45. doi:
10.1016/j.clpt.2006.05.006. [PMID: 16952490] - Nathalie K Zgheib, Reginald F Frye, Timothy S Tracy, Marjorie Romkes, Robert A Branch. Validation of incorporating flurbiprofen into the Pittsburgh cocktail.
Clinical pharmacology and therapeutics.
2006 Sep; 80(3):257-63. doi:
10.1016/j.clpt.2006.06.005. [PMID: 16952492] - Maori Mitsuda, Masahiko Iwasaki, Satoru Asahi. Cynomolgus monkey cytochrome P450 2C43: cDNA cloning, heterologous expression, purification and characterization.
Journal of biochemistry.
2006 May; 139(5):865-72. doi:
10.1093/jb/mvj093. [PMID: 16751594] - Sonja Krösser, Roland Neugebauer, Hugues Dolgos, Markus Fluck, Karl-Ludwig Rost, Andreas Kovar. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.
European journal of clinical pharmacology.
2006 Apr; 62(4):277-84. doi:
10.1007/s00228-006-0101-7. [PMID: 16525816] - Britt Jansson, Doaa Elsherbiny, Ulrika S H Simonsson. Enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma and urine by liquid chromatography/tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM.
2006; 20(3):463-72. doi:
10.1002/rcm.2324. [PMID: 16395737] - Sarah C Sim, Carl Risinger, Marja-Liisa Dahl, Eleni Aklillu, Magnus Christensen, Leif Bertilsson, Magnus Ingelman-Sundberg. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
Clinical pharmacology and therapeutics.
2006 Jan; 79(1):103-13. doi:
10.1016/j.clpt.2005.10.002. [PMID: 16413245] - D Tomalik-Scharte, A Jetter, M Kinzig-Schippers, A Skott, F Sörgel, T Klaassen, D Kasel, S Harlfinger, O Doroshyenko, D Frank, J Kirchheiner, M Bräter, K Richter, T Gramatté, U Fuhr. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers.
Drug metabolism and disposition: the biological fate of chemicals.
2005 Dec; 33(12):1859-66. doi:
10.1124/dmd.105.005272. [PMID: 16183781] - Christian Puozzo, Simone Lens, Christian Reh, Karl Michaelis, Dominique Rosillon, Xavier Deroubaix, Dominique Deprez. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants.
Clinical pharmacokinetics.
2005; 44(9):977-88. doi:
10.2165/00003088-200544090-00007. [PMID: 16122284] - Zourab Bebia, Shama C Buch, John W Wilson, Reginald F Frye, Marjorie Romkes, Alfred Cecchetti, Diego Chaves-Gnecco, Robert A Branch. Bioequivalence revisited: influence of age and sex on CYP enzymes.
Clinical pharmacology and therapeutics.
2004 Dec; 76(6):618-27. doi:
10.1016/j.clpt.2004.08.021. [PMID: 15592333] - Lian-Sheng Wang, Bing Zhu, A M Abd El-Aty, Gan Zhou, Zhi Li, Jun Wu, Guo-Lin Chen, Jie Liu, Zhi Rong Tang, Wang An, Qing Li, Dan Wang, Hong-Hao Zhou. The influence of St John's Wort on CYP2C19 activity with respect to genotype.
Journal of clinical pharmacology.
2004 Jun; 44(6):577-81. doi:
10.1177/0091270004265642. [PMID: 15145964] - Ophelia Q P Yin, Brian Tomlinson, Albert H L Chow, Mary M Y Waye, Moses S S Chow. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
Journal of clinical pharmacology.
2004 Jun; 44(6):582-9. doi:
10.1177/0091270004265702. [PMID: 15145965] - Y Naritomi, S Terashita, A Kagayama. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate.
Xenobiotica; the fate of foreign compounds in biological systems.
2004 May; 34(5):415-27. doi:
10.1080/00498250410001685728. [PMID: 15370958] - Kyoung-Ah Kim, Ji-Suk Lee, Hi-Joon Park, Jin-Woo Kim, Chang-Ju Kim, In-Sop Shim, Nam-Jae Kim, Seung-Moo Han, Sabina Lim. Inhibition of cytochrome P450 activities by oleanolic acid and ursolic acid in human liver microsomes.
Life sciences.
2004 Apr; 74(22):2769-79. doi:
10.1016/j.lfs.2003.10.020. [PMID: 15043991] - Tobias Klaassen, Dirk Kasel, Stefanie Harlfinger, Uwe Fuhr. Quantification of mephenytoin and its metabolites 4'-hydroxymephenytoin and nirvanol in human urine using a simple sample processing method.
Rapid communications in mass spectrometry : RCM.
2004; 18(15):1675-80. doi:
10.1002/rcm.1539. [PMID: 15282764] - Karin Herrlin, Norio Yasui-Furukori, Gunnel Tybring, Jolanta Widén, Lars L Gustafsson, Leif Bertilsson. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes.
British journal of clinical pharmacology.
2003 Oct; 56(4):415-21. doi:
10.1046/j.1365-2125.2003.01874.x. [PMID: 12968986] - Francine Prost, Wolfgang Thormann. Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes): application to the chiral metabolism of mephenytoin and methadone.
Electrophoresis.
2003 Aug; 24(15):2577-87. doi:
10.1002/elps.200305493. [PMID: 12900870] - Britt Jansson, Ulrika S H Simonsson, Michael Ashton. Simultaneous enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma by liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2003 Jul; 791(1-2):179-91. doi:
10.1016/s1570-0232(03)00221-6. [PMID: 12798178] - Caiping Yao, Kent L Kunze, William F Trager, Evan D Kharasch, René H Levy. Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.
Drug metabolism and disposition: the biological fate of chemicals.
2003 May; 31(5):565-71. doi:
10.1124/dmd.31.5.565. [PMID: 12695344] - Bang Qian Xu, Mikio Ishii, Li Rong Ding, Nancy E Fischer, Tadanobu Inaba. Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6.
Life sciences.
2003 Mar; 72(17):1953-62. doi:
10.1016/s0024-3205(03)00093-6. [PMID: 12597994] - Xiao-Ping Chen, Zhi-Rong Tan, Song-Lin Huang, Zheng Huang, Dong-Sheng Ou-Yang, Hong-Hao Zhou. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects.
Clinical pharmacology and therapeutics.
2003 Mar; 73(3):264-71. doi:
10.1067/mcp.2003.14. [PMID: 12621391] - Meera Vaswani, Farzana Kadar Linda, Subramanyam Ramesh. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review.
Progress in neuro-psychopharmacology & biological psychiatry.
2003 Feb; 27(1):85-102. doi:
10.1016/s0278-5846(02)00338-x. [PMID: 12551730] - Thomas D Nolin, Reginald F Frye. Stereoselective determination of the CYP2C19 probe drug mephenytoin in human urine by gas chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2003 Jan; 783(1):265-71. doi:
10.1016/s1570-0232(02)00676-1. [PMID: 12450547] - Reginald F Frye, Virginia M Schneider, Carole S Frye, Arthur M Feldman. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure.
Journal of cardiac failure.
2002 Oct; 8(5):315-9. doi:
10.1054/jcaf.2002.127773. [PMID: 12411982] - Nan He, Feng-Xiang Yan, Song-Lin Huang, Wei Wang, Zhou-Sheng Xiao, Zhao-Qian Liu, Hong-Hao Zhou. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
European journal of clinical pharmacology.
2002 Apr; 58(1):15-8. doi:
10.1007/s00228-002-0425-x. [PMID: 11956668] - Ji-Yeon Kim, Sooyong Lee, Dong-Hyun Kim, Bok-Ryang Kim, RaeKil Park, Byung Mu Lee. Effects of flavonoids isolated from Scutellariae radix on cytochrome P-450 activities in human liver microsomes.
Journal of toxicology and environmental health. Part A.
2002 Mar; 65(5-6):373-81. doi:
10.1080/15287390252808046. [PMID: 11936218] - Lars Brachtendorf, Alexander Jetter, K Tobias Beckurts, Arnulf H Hölscher, Uwe Fuhr. Cytochrome P450 enzymes contributing to demethylation of maprotiline in man.
Pharmacology & toxicology.
2002 Mar; 90(3):144-9. doi:
10.1034/j.1600-0773.2002.900306.x. [PMID: 12071336] - Gesche Jürgens, Kai Henrik Wiborg Lange, Lene Ørskov Reuther, Birgitte Buur Rasmussen, Kim Brøsen, Hanne Rolighed Christensen. Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men.
Clinical pharmacology and therapeutics.
2002 Mar; 71(3):162-8. doi:
10.1067/mcp.2002.121373. [PMID: 11907490] - Ayman Al-Shurbaji, Juliette Säwe. The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype.
European journal of clinical pharmacology.
2002 Feb; 57(12):877-81. doi:
10.1007/s00228-001-0413-6. [PMID: 11936707] - Reginald F Frye, Robert A Branch. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
British journal of clinical pharmacology.
2002 Feb; 53(2):155-62. doi:
10.1046/j.1365-2125.2002.01522.x. [PMID: 11851639] - Enock Delaporte, A David Rodrigues. Cytochrome p450 assays.
Current protocols in pharmacology.
2002 Feb; Chapter 3(?):Unit3.9. doi:
10.1002/0471141755.ph0309s15. [PMID: 21959765] - J L Palmer, R J Scott, A Gibson, M Dickins, S Pleasance. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
British journal of clinical pharmacology.
2001 Nov; 52(5):555-61. doi:
10.1046/j.0306-5251.2001.01479.x. [PMID: 11736864] - B Zhu, D S Ou-Yang, X P Chen, S L Huang, Z R Tan, N He, H H Zhou. Assessment of cytochrome P450 activity by a five-drug cocktail approach.
Clinical pharmacology and therapeutics.
2001 Nov; 70(5):455-61. doi:
10.1067/mcp.2001.119813. [PMID: 11719732] - S A Cherstniakova, D Bi, D R Fuller, J Z Mojsiak, J M Collins, L R Cantilena. Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes.
Drug metabolism and disposition: the biological fate of chemicals.
2001 Sep; 29(9):1216-20. doi:
. [PMID: 11502731] - K Brøsen, C A Naranjo. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.
2001 Aug; 11(4):275-83. doi:
10.1016/s0924-977x(01)00101-8. [PMID: 11532381] - C B Eap, G Bondolfi, D Zullino, C Bryois, M Fuciec, L Savary, M Jonzier-Perey, P Baumann. Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test.
Therapeutic drug monitoring.
2001 Jun; 23(3):228-31. doi:
10.1097/00007691-200106000-00008. [PMID: 11360030] - K Laine, M Anttila, L Nyman, A Wahlberg, L Bertilsson. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline.
European journal of clinical pharmacology.
2001 May; 57(2):137-42. doi:
10.1007/s002280100289. [PMID: 11417445] - A T Harvey, S H Preskorn. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers.
Journal of clinical psychopharmacology.
2001 Apr; 21(2):161-6. doi:
10.1097/00004714-200104000-00007. [PMID: 11270912] - A Hadama, I Ieiri, T Morita, M Kimura, A Urae, S Irie, T Kaneda, K Mamiya, N Tashiro, S Higuchi, K Otsubo. P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism.
Therapeutic drug monitoring.
2001 Apr; 23(2):115-8. doi:
10.1097/00007691-200104000-00004. [PMID: 11294510] - M Tanaka, T Ohkubo, K Otani, A Suzuki, S Kaneko, K Sugawara, Y Ryokawa, T Ishizaki. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin.
Clinical pharmacology and therapeutics.
2001 Mar; 69(3):108-13. doi:
10.1067/mcp.2001.113723. [PMID: 11240974] - T W Yao, S Zeng, T W Wang, S Q Chen. Phenotype analysis of cytochrome P450 2C19 in Chinese subjects with mephenytoin S/R enantiomeric ratio in urine measured by chiral GC.
Biomedical chromatography : BMC.
2001 Feb; 15(1):9-13. doi:
10.1002/bmc.19. [PMID: 11180294] - M Britzi, M Bialer, L Arcavi, A Shachbari, T Kapitulnik, S Soback. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.
Therapeutic drug monitoring.
2000 Oct; 22(5):510-6. doi:
10.1097/00007691-200010000-00002. [PMID: 11034254] - K Laine, G Tybring, L Bertilsson. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects.
Clinical pharmacology and therapeutics.
2000 Aug; 68(2):151-9. doi:
10.1067/mcp.2000.108949. [PMID: 10976546] - J W Ko, Z Desta, N V Soukhova, T Tracy, D A Flockhart. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.
British journal of clinical pharmacology.
2000 Apr; 49(4):343-51. doi:
10.1046/j.1365-2125.2000.00175.x. [PMID: 10759690] - A L Buchwald. Mephenytoin overdose--phenytoin poisoning incognito? Case report and mephenytoin/phenytoin comparison.
Journal of toxicology. Clinical toxicology.
2000; 38(7):781-5. doi:
10.1081/clt-100102392. [PMID: 11192466] - P Sandwall, M W Lo, B Jonzon, P Dalén, C Furtek, M Ritter, G Alván, J McCrea, F Sjöqvist. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
European journal of clinical pharmacology.
1999 Jun; 55(4):279-83. doi:
10.1007/s002280050629. [PMID: 10424320] - S Sviri, S Shpizen, E Leitersdorf, M Levy, Y Caraco. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.
Clinical pharmacology and therapeutics.
1999 Mar; 65(3):275-82. doi:
10.1016/s0009-9236(99)70106-2. [PMID: 10096259] - S Kortunay, A Bozkurt, L Bathum, N E Basci, M Calgüneri, K Brøsen, S O Kayaalp. CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus.
Annals of the rheumatic diseases.
1999 Mar; 58(3):182-5. doi:
10.1136/ard.58.3.182. [PMID: 10364917] - S L Huang, H G Xie, W Wang, Z H Xu, C H Jiang, H H Zhou. Determination of S/R ratio of mephenytoin in human urine by chiral HPLC and ultraviolet detection and its comparison with gas chromatography.
Zhongguo yao li xue bao = Acta pharmacologica Sinica.
1998 Nov; 19(6):548-50. doi:
NULL. [PMID: 10437143] - K Herrlin, A Y Massele, M Jande, C Alm, G Tybring, Y A Abdi, A Wennerholm, I Johansson, M L Dahl, L Bertilsson, L L Gustafsson. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
Clinical pharmacology and therapeutics.
1998 Oct; 64(4):391-401. doi:
10.1016/s0009-9236(98)90070-4. [PMID: 9797796] - T Yao, S Zeng, H Ruan, S Chen. [Determination of mephenytoin enantiomers in human urine using chiral capillary chromatography and its application in metabolism polymorphism study].
Se pu = Chinese journal of chromatography.
1998 Sep; 16(5):408-10. doi:
NULL. [PMID: 11498919] - A Adedoyin, P A Arns, W O Richards, G R Wilkinson, R A Branch. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
Clinical pharmacology and therapeutics.
1998 Jul; 64(1):8-17. doi:
10.1016/s0009-9236(98)90017-0. [PMID: 9695714] - C B Eap, T Buclin, P A Buchwalder, N Gutmann, P Baumann. Multiple and simultaneous phenotyping tests: beware of ascorbic acid when determining the mephenytoin (S)/(R) ratio.
Clinica chimica acta; international journal of clinical chemistry.
1998 Mar; 271(1):105-7. doi:
10.1016/s0009-8981(97)00242-8. [PMID: 9564562] - H J Feng, S L Huang, W Wang, H H Zhou. The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose.
British journal of clinical pharmacology.
1998 Jan; 45(1):27-9. doi:
10.1046/j.1365-2125.1998.00643.x. [PMID: 9489590] - M Tanaka, T Ohkubo, K Otani, A Suzuki, S Kaneko, K Sugawara, Y Ryokawa, H Hakusui, S Yamamori, T Ishizaki. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
Clinical pharmacology and therapeutics.
1997 Dec; 62(6):619-28. doi:
10.1016/s0009-9236(97)90081-3. [PMID: 9433390] - P A Arns, A Adedoyin, A M DiBisceglie, J G Waggoner, J H Hoofnagle, G R Wilkinson, R A Branch. Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitis.
Clinical pharmacology and therapeutics.
1997 Nov; 62(5):527-37. doi:
10.1016/s0009-9236(97)90048-5. [PMID: 9390109] - G Tybring, J Nordin, T Bergman, L Bertilsson. An S-mephenytoin cysteine conjugate identified in urine of extensive but not of poor metabolizers of S-mephenytoin.
Pharmacogenetics.
1997 Oct; 7(5):355-60. doi:
10.1097/00008571-199710000-00003. [PMID: 9352570] - Y Böttiger, G Tybring, E Götharson, L Bertilsson. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin.
Clinical pharmacology and therapeutics.
1997 Oct; 62(4):384-91. doi:
10.1016/s0009-9236(97)90116-8. [PMID: 9357389] - R F Frye, G R Matzke, A Adedoyin, J A Porter, R A Branch. Validation of the five-drug 'Pittsburgh cocktail' approach for assessment of selective regulation of drug-metabolizing enzymes.
Clinical pharmacology and therapeutics.
1997 Oct; 62(4):365-76. doi:
10.1016/s0009-9236(97)90114-4. [PMID: 9357387] - U Jeppesen, B B Rasmussen, K Brøsen. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide.
Clinical pharmacology and therapeutics.
1997 Sep; 62(3):279-86. doi:
10.1016/s0009-9236(97)90030-8. [PMID: 9333103] - S Huang, H Xie, W Wang, Z Xu, C Jiang, H Zhou. [Determination of R- and S-mephenytoin in human urine by gas chromatography].
Se pu = Chinese journal of chromatography.
1997 Sep; 15(5):408-10. doi:
NULL. [PMID: 15739491] - T Sarich, T Kalhorn, S Magee, F al-Sayegh, S Adams, J Slattery, J Goldstein, S Nelson, J Wright. The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin.
Clinical pharmacology and therapeutics.
1997 Jul; 62(1):21-8. doi:
10.1016/s0009-9236(97)90148-x. [PMID: 9246016] - D R Sohn, J T Kwon, H K Kim, T Ishizaki. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
Clinical pharmacology and therapeutics.
1997 May; 61(5):574-82. doi:
10.1016/s0009-9236(97)90137-5. [PMID: 9164419] - H G Xie, Z H Xu, S L Huang, J H Liu, J X Wu, C H Jiang, H H Zhou. No correlation between side-chain of propranolol oxidation and S-mephenytoin 4'-hydroxylase activity.
Zhongguo yao li xue bao = Acta pharmacologica Sinica.
1997 May; 18(3):216-8. doi:
NULL. [PMID: 10072936] - H G Xie, S L Huang, Z H Xu, Z S Xiao, N He, H H Zhou. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population.
Pharmacogenetics.
1997 Apr; 7(2):115-9. doi:
10.1097/00008571-199704000-00004. [PMID: 9170148] - K Otani, N Yasui, S Kaneko, T Ohkubo, T Osanai, K Sugawara, K Hayashi, K Chiba, T Ishizaki. Effects of genetically determined S-mephenytoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
1997 Jan; 16(1):8-14. doi:
10.1016/s0893-133x(96)00165-0. [PMID: 8981384] - S Kortunay, N E Basci, A Bozkurt, A Isimer, A Sayal, S O Kayaalp. The hydroxylation of omeprazole correlates with S-mephenytoin and proguanil metabolism.
European journal of clinical pharmacology.
1997; 53(3-4):261-4. doi:
10.1007/s002280050373. [PMID: 9476042] - N E Basci, A Bozkurt, S Kortunay, A Isimer, A Sayal, S O Kayaalp. Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population.
British journal of clinical pharmacology.
1996 Dec; 42(6):771-3. doi:
10.1046/j.1365-2125.1996.00500.x. [PMID: 8971434] - Y Böttiger, P Dostert, M S Benedetti, M Bani, F Fiorentini, M Casati, I Poggesti, C Alm, G Alvan, L Bertilsson. Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.
British journal of clinical pharmacology.
1996 Dec; 42(6):707-11. doi:
10.1046/j.1365-2125.1996.00471.x. [PMID: 8971425] - P Dalén, G Alvan, M Wakelkamp, H Olsen. Formation of meprobamate from carisoprodol is catalysed by CYP2C19.
Pharmacogenetics.
1996 Oct; 6(5):387-94. doi:
10.1097/00008571-199610000-00002. [PMID: 8946470] - J Wan, H Xia, N He, Y Q Lu, H H Zhou. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype.
British journal of clinical pharmacology.
1996 Oct; 42(4):471-4. doi:
10.1046/j.1365-2125.1996.42712.x. [PMID: 8904619] - Y Caraco, G R Wilkinson, A J Wood. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole.
Clinical pharmacology and therapeutics.
1996 Oct; 60(4):396-404. doi:
10.1016/s0009-9236(96)90196-4. [PMID: 8873687] - M Jurima-Romet, J A Goldstein, M LeBelle, R A Aubin, B C Foster, W Walop, A Rode. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population.
Pharmacogenetics.
1996 Aug; 6(4):329-39. doi:
10.1097/00008571-199608000-00006. [PMID: 8873219] - E Koyama, T Tanaka, K Chiba, S Kawakatsu, S Morinobu, S Totsuka, T Ishizaki. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
Journal of clinical psychopharmacology.
1996 Aug; 16(4):286-93. doi:
10.1097/00004714-199608000-00003. [PMID: 8835703] - P Baumann, R Nil, A Souche, S Montaldi, D Baettig, S Lambert, C Uehlinger, A Kasas, M Amey, M Jonzier-Perey. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation.
Journal of clinical psychopharmacology.
1996 Aug; 16(4):307-14. doi:
10.1097/00004714-199608000-00006. [PMID: 8835706] - Y Caraco, P O Lagerstrom, A J Wood. Ethnic and genetic determinants of omeprazole disposition and effect.
Clinical pharmacology and therapeutics.
1996 Aug; 60(2):157-67. doi:
10.1016/s0009-9236(96)90131-9. [PMID: 8823233] - C B Eap, T W Guentert, M Schãublin-Loidl, M Stabl, L Koeb, K Powell, P Baumann. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.
Clinical pharmacology and therapeutics.
1996 Mar; 59(3):322-31. doi:
10.1016/s0009-9236(96)80010-5. [PMID: 8653995] - Z R Ruan, Y S Cheng, J F Zhou, Y Zhao, Y Z Pan, D Y Ding. Genetic polymorphism of 4'-hydroxylation of S-mephenytoin in 148 Chinese of Han nationality.
Zhongguo yao li xue bao = Acta pharmacologica Sinica.
1996 Mar; 17(2):119-21. doi:
NULL. [PMID: 9772658]
